79
Views
0
CrossRef citations to date
0
Altmetric
Short Communication

Differences in Severity of Poison Centers Exposures Involving XTAMPZA® ER Versus Other Opioid Analgesics

, , &
Pages 519-527 | Received 05 Sep 2022, Accepted 08 Aug 2023, Published online: 18 Oct 2023
 

Abstract

Aims: Xtampza® ER (Collegium Pharmaceutical, MA, USA) is an abuse-deterrent formulation (ADF) of oxycodone intended to deter tampering for use by unintended routes of administration. We assessed whether Xtampza ER exposures were less likely to result in severe medical outcomes relative to other opioid analgesic exposures. Materials & methods: Exposures reported to participating poison centers between 2016 and 2021 inclusive that were followed to a known medical outcome were analyzed. Xtampza ER was compared with other ADF opioids, non-ADF extended-release opioids, single-entity oxycodone immediate-release, unspecified oxycodone and unspecified morphine. Results & conclusion: No Xtampza ER exposures involved unintended routes of administration. Xtampza ER exposures were less likely to be abuse, misuse or suspected suicidal, and medical outcomes were less severe than comparators.

Tweetable abstract

Xtampza ER exposures reported to poison centers tended to be less severe than comparators. Xtampza ER exposures were less likely to be classified as abuse, misuse or unknown intentional exposure than comparators. No Xtampza ER exposures involved injection or inhalation use.

Financial & competing interests disclosure

This study was funded by Collegium Pharmaceutical.

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The Poison Center Program study protocol received its most recent review and approval from the Colorado Multiple Institutional Review Board (COMIRB) on 30 April 2021. In addition, the study protocol was reviewed and approved by the Institutional Review Board of each participating poison center.

Supplementary data

Additional information

Funding

This study was funded by Collegium Pharmaceutical. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 412.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.